W. D. Brok

Detection of circulating plasma tumour mutations in early stage triple negative breast cancer as an adjunct to pathological complete response assessment.

S. Aparicio, C. Lohrisch, C. Bates, 2023, medRxiv.

Targeting triple-negative breast cancer: optimizing therapeutic outcomes – UPDATE

K. Gelmon, W. D. D. Brok, W. D. Brok, 2016 .